AstraZeneca signs $2 bln agreement with Quell to develop cell therapies

FILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustrationFILE PHOTO: Test tubes are seen in front of a displayed AstraZeneca logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration

  • AstraZeneca PLCFollow
  • Quell Therapeutics LimitedFollow

June 9 (Reuters) – AstraZeneca (AZN.L) said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.

The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications, the drugmaker said in a statement.

UK-based Quell will receive $85 million upfront from AstraZeneca, and is also eligible to receive over $2 billion for further development and commercialisation milestones, the company added.

  • Climate ChangecategoryWhat health experts say wildfire smoke novices need to knowJune 8, 2023
  • United KingdomcategoryGSK employees to escalate strike action in June -unionJune 8, 2023
  • article with videoWorldcategoryHIV alarm in Uganda as anti-gay law forces LGBT 'lockdown'June 8, 2023
  • Mergers & AcquisitionscategoryNovartis' Sandoz wagers its standalone future on biosimilar successJune 8, 2023


Related posts

Oil falls on demand concerns, greater supply

Cynthia Danforth

Volkswagen investors renew governance gripes, despite special dividend

Cynthia Danforth

Oil climbs as dollar slips and supply risks linger

Cynthia Danforth

Leave a Comment